India, July 10 -- Hansoh Pharmaceutical Group, the licensor of GSK's investigational therapy Ris-Rez, announced positive Phase III results from its ARTEMIS-008 study in China, marking a major milestone in small-cell lung cancer research.
The trial met its primary endpoint, showing statistically significant and clinically meaningful improvements in overall survival (OS) compared with the current standard of care, Topotecan.
Conducted in patients with advanced or relapsed in small-cell lung cancer (SCLC), the study also demonstrated consistent benefits across secondary endpoints, including progression-free survival, with a safety profile in line with earlier findings and no new safety signals. These results represent the first pivotal Phase...